Evidence map›Paper›PMID 28117136›Full record

ReviewJournal of cystic fibrosis : official journal of the European Cystic Fibrosis Society2017

Use of FEV

Rhonda Szczesniak, Sonya L Heltshe, Sanja Stanojevic, Nicole Mayer-Hamblett

Abstract readReview
In one paragraph

Review in Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. The measurement properties of tests and tools used in cystic fibrosis studies: a systematic review.European respiratory review : an official journal of the European Respiratory Society · 2021
    Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Effect of caregiver burden on the quality of life of informal caregivers of people with cystic fibrosis in the United Kingdom: a cross-sectional study.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025
    Article
  10. Comparison of the Effect of CFTR ModulatorsJournal of clinical medicine · 2025
    Article
  11. Article
  12. Baseline-dependent improvement in CF studies, plausibility of bias.Contemporary clinical trials communications · 2024
    Article
  13. Impact of day-to-day variation in FEV1 on measures of change: A conceptual description.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2024
    Article
  14. Observational
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Epidemiology and impact of methicillin-sensitiveAntimicrobial agents and chemotherapy · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Rhonda SzczesniakDivision of Biostatistics & Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA; Division of Pulmonary Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA. Electronic address: Rhonda.Szczesniak@cchmc.org.
Sonya L HeltsheDepartment of Pediatrics, University of Washington, Seattle, WA, USA; Cystic Fibrosis Foundation Therapeutics Development Network Coordinating Center, Seattle Children's Research Institute, Seattle, WA, USA.
Sanja StanojevicDivision of Respiratory Medicine, Hospital for Sick Children, Toronto, ON, Canada.
Nicole Mayer-HamblettDepartment of Pediatrics, University of Washington, Seattle, WA, USA; Cystic Fibrosis Foundation Therapeutics Development Network Coordinating Center, Seattle Children's Research Institute, Seattle, WA, USA; Department of Biostatistics, University of Washington, Seattle, WA, USA.

Funding

Institute of Translational Health SciencesUL1TR000423 · NCATS · UNIVERSITY OF WASHINGTON · PI DISIS, MARY L. · 2012 to 2016
$49.4M
Translational Research Center to Expedite Novel Therapies in Cystic FibrosisP30DK089507 · NIDDK · SEATTLE CHILDREN'S HOSPITAL · PI Christopher Hooper Goss · 2010 to 2026
$21.4M
Preventing rapid decline in CF: statistical research career commitmentK25HL125954 · NHLBI · CINCINNATI CHILDRENS HOSP MED CTR · PI SZCZESNIAK, RHONDA · 2015 to 2019
$762k
NCATS NIH HHS UL1 TR000423NHLBI NIH HHS K25 HL125954NIDDK NIH HHS P30 DK089507
6 · The paper itself

Abstract

backgroundForced expiratory volume in 1s (FEV

resultsIn this review, we summarize from a statistical perspective the clinical relevance of FEV

conclusionsOur understanding of CF disease course, therapeutics, and clinical care has evolved immensely in the past decades, in large part due to the thoughtful application of rigorous research methods and meaningful clinical endpoints such as FEV

Indexed as

Cystic FibrosisForced Expiratory VolumeComparative Effectiveness ResearchDisease ProgressionEpidemiologic StudiesHumansDisease progressionFEV(1) endpointsLongitudinalLung functionSpirometry

Identifiers

PMID28117136
PMCPMC5420487

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.